Celltrion And Pfizer Cement Victory On Infliximab

Janssen's Cell-Culture Media Patent Not Infringed By Inflectra/Remsima

 
• By Dean Rudge

Celltrion and Pfizer are now two for two in their legal battles with Janssen over US patents shielding the originator's Remicade (infliximab), with a US Court of Appeals once again siding with the biosimilars developers.

Gavel
Celltrion and Pfizer have the backing of an appeals court for their biosimilar infliximab • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin